REACH: Study to Determine the Aetiology of Chlormethine Gel Induced-skin Drug Reaction in Early Stage Mycosis Fungoides Cutaneous T Cell Lymphoma (MF-CTCL)
Launched by EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER - EORTC · Jan 3, 2020
Trial Information
Current as of June 18, 2025
Terminated
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diagnosis of MF-CTCL stage IA or IB at enrolment as per ISCL/EORTC revision to the MF and Sézary syndrome classification and MF stage should have never met the criteria for stage IIA or higher in the patient medical history
- • Lesions cover less than 80% of BSA
- • Age ≥ 18
- • ECOG/WHO performance status 0-2
- Exclusion Criteria:
- • Previous treatment with CL gel
- • Concurrent or planned local or systemic anti-CTCL therapy
- • Prior treatment with antihistamines or narrow band UV-B or PUVA therapy one week before enrolment, or systemic corticosteroids or radiotherapy in the last 4 weeks before enrolment
- • Prior treatment with topical steroids in the patch test area (upper back) one week before enrolment
About European Organisation For Research And Treatment Of Cancer Eortc
The European Organisation for Research and Treatment of Cancer (EORTC) is a prominent non-profit organization dedicated to advancing cancer research and improving patient care through innovative clinical trials. Established in 1962, EORTC fosters collaboration among international researchers, healthcare professionals, and institutions to develop and implement rigorous clinical studies that evaluate novel therapies and treatment strategies. With a strong commitment to enhancing the quality of life for cancer patients, EORTC focuses on multidisciplinary approaches and the integration of patient-reported outcomes, ensuring that its findings translate effectively into clinical practice and contribute to the global fight against cancer.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bordeaux, , France
Paris, , France
Patients applied
Trial Officials
Julia Scarisbrick, MD
Study Chair
UHB-Queen Elisabeth Medical Centre, Birmingham, United Kingdom
Emmanuella Guenova, MD
Study Chair
Centre Hospitalier Universitaire Vaudois - Lausanne, Lausanne, Switzerland
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials